Dr Andrew Retter, Chief Medical Officer at Volition said: "We are excited to report the findings of this large-scale independent clinical study, the culmination of many years work. Nu.Q® NETs ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with a leading pharmaceutical company to utilize Volition's ...

A live question and answer session will follow the formal presentations. About Dr. Andrew Retter Andrew Retter, BSc (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care ...